 |
|
|
| |
Cobicistat versus Ritonavir
as Pharmacoenhancers of Atazanavir in
Combination with Emtricitabine/Tenofovir DF -
Phase 3 Randomized, Blinded, Active-Controlled Trial,
Week 144 Results
|
| |
| |
Reported by Jules Levin
ICAAC
54th Interscience Conference on Antimicrobial Agents and Chemotherapy
Washington, DC
September 5-9, 2014
J. Gallant1, E. Koenig2, J. Andrade-Villanueva3, P. Chetchotisakd4, E. DeJesus5, F. Antunes6, K. Arasteh7, G. Moyle8, G. Rizzardini9 J. Fehr10, H. Lui11, L. Zhong11, M. Abram11, H. Cao11, A. Cheng11, and J. Szwarcberg11
1Southwest Care Center, Santa Fe, NM, US; 2Instituto Dominicano de Estudios Virologicos -IDEV-, Santo Domingo, Dominican Republic; 3Hospital Civil, Guadalajara, Mexico; 4Khon Kaen University, Muang District, Thailand; 5Orlando Immunology Center, Orlando, US; 6Hospital de Santa Maria, Lisboa, Portugal; 7EPIMED / Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 8Chelsea & Westminster Hospital, London, United Kingdom; 9Ospedale Luigi Sacco, Milano, Italy; 10University Hospital Zurich, Zurich, Switzerland; 11Gilead Sciences, Inc., Foster City, US
|
| |
|
|
|
|
|
